Reduction in duration of neutropenia & incidence of febrile neutropenia in patients treated w/ cytotoxic chemotherapy for malignancy. Decrease the risk of febrile neutropenia in patients w/ non-myeloid malignancies receiving myelosuppressive antineoplastic cytotoxic chemotherapy that is associated w/ clinically important risk of severe neutropenia w/ fever.
Splenic rupture; adult resp distress syndrome; sickle cell disease; permanently discontinue in patients w/ serious allergic reactions. Do not administer during 14 days before or 24 hr after cytotoxic chemotherapy. Potential effect on malignant cells; bone pain. Pregnancy & lactation. Infant, childn & adolescent <45 kg.
Sign Out
